Cytoguide Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Cytoguide General Information

Description

Developer of combined drugs that target receptors on cells in pathological tissues. The company offers drugs that are aimed to improve the treatment of onocyte and macrophage-related diseases including autoimmune disease, leukemia and other infectious diseases.

Contact Information

Website
cytoguide.dk
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • INCUBA Science Park
  • Gustav Wieds Vej 10
  • 8200 Aarhus
  • Denmark
+45 86
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Corporate Office
  • INCUBA Science Park
  • Gustav Wieds Vej 10
  • 8200 Aarhus
  • Denmark
+45 86

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cytoguide Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 01-Oct-2013 Completed Generating Revenue
4. Early Stage VC 08-Dec-2010 Completed Startup
3. Early Stage VC 02-Jun-2009 Completed Startup
2. Early Stage VC 28-Nov-2008 $2.39M $2.68M Completed Startup
1. Seed Round 01-Nov-2007 $287K $287K Completed Startup
To view Cytoguide’s complete valuation and funding history, request access »

Cytoguide Patents

Cytoguide Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2013093465-A3 Formulations Inactive 23-Dec-2011
WO-2013093465-A2 Novel formulations Inactive 23-Dec-2011
US-20020155995-A1 Haptoglobin-haemoglobin complex or a part thereof or a mimic thereof being operably linked to a substance; capable of binding a cd163 receptor and/or a cd163 receptor variant. Inactive 22-Feb-2001
US-20050063951-A1 Haptoglobin-hemoglobin (hp-hb) complex capable of binding a cd163 receptor, conjugated to another active agent such as an antimicrobial agent, an anticancer drug, an anti-hiv drug; gene therapy of sickle cell anemia for example Inactive 22-Feb-2001
DE-60140069-D1 Function of a haptoglobin hemoglobin receptor and application therefor Inactive 16-Oct-2000 G01N33/721
To view Cytoguide’s complete patent history, request access »

Cytoguide Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Capnova Venture Capital Minority
KDventures Venture Capital Minority
Lund University Bioscience Venture Capital Minority
Novo Holdings Venture Capital Minority
To view Cytoguide’s complete investors history, request access »

Cytoguide FAQs

  • When was Cytoguide founded?

    Cytoguide was founded in 2007.

  • Where is Cytoguide headquartered?

    Cytoguide is headquartered in Aarhus, Denmark.

  • What industry is Cytoguide in?

    Cytoguide’s primary industry is Drug Discovery.

  • Is Cytoguide a private or public company?

    Cytoguide is a Private company.

  • What is Cytoguide’s current revenue?

    The current revenue for Cytoguide is .

  • How much funding has Cytoguide raised over time?

    Cytoguide has raised $2.68M.

  • Who are Cytoguide’s investors?

    Capnova, KDventures, Lund University Bioscience, and Novo Holdings have invested in Cytoguide.

  • When was Cytoguide acquired?

    Cytoguide was acquired on 01-Oct-2013.

  • Who acquired Cytoguide?

    Cytoguide was acquired by Affinicon.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process